182747-25-7

Upstream product

• 32276-77-0 mercuric trimethylacetate 
• 101623-69-2 (1-chloroethyl)-(4-nitrophenyl)carbonate 
• 100-02-7 4-nitro-phenol 
• 75-98-9 Trimethylacetic acid 

Downstream Products

• 246519-33-5 (4R,5S,6S)-3-((2R,3R)-2-{[1-(2,2-dimethyl-propionyloxy)ethoxycarbonylamino]-methyl}-tetrahydrofuran-3-yl-sulfanyl)-6-(1R-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 4-nitrophenylmethyl ester 
• 1201167-82-9 1-((S)-1-{2-[2-(tert-butoxycarbonylamino)ethyl]phenylamino}-5-nitroguanidinopentan-2-ylcarbamolyoxy)ethyl pivalate 

Relevant academic research and scientific papers

Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy

Synthesis and bioactivity of novel dual acting nitric oxide releasing and reactive oxygen scavenging hybrid compound SA-2 is described. The hybrid molecule SA-2 significantly increased the superoxide dismutase enzyme level and protected the photoreceptor

AZETIDINE DERIVATIVE, AND PRODRUG THEREOF

An object of the present invention is to provide a compound useful as a therapeutic or prophylactic drug for a disease involving the immune system, by suppressing a function of immune cells by suppressing proliferation of activated T cells or suppressing production of interferon alpha (IFN-α) by activated plasmacytoid dendritic cells (pDC), particularly an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis in SLE patients. The present invention provides a compound represented by general formula (I) : [wherein X, R1, R2, R3, R4, R5 and R6 are as described in the description], or a pharmaceutically acceptable salt thereof.

Convergent syntheses of oral THF 1β-methylcarbapenems

Convergent syntheses of oral THF 1β-methylcarbapenems 4 (OCA-983) and 5 starting from M2-phosphate 1 were developed. Reaction of the M2-phosphate 1 with THF thiols containing a requisite prodrug side chain, 9 and 10, gave the desired oral THF 1β-methylcarbapenems 4 and 5, respectively, in 46% and 42% overall yields.

Mono and bis double ester prodrugs of novel aminomethyl-THF 1β-methylcarbapenems

Mono and bis double ester prodrugs of aminomethyl THF 1β-methylcarbapenems 1 were Mono double ester derivatives (2, 4 and 7) did not demonstrate significantly improved oral activity due to the presence of the charged species. However, bis double ester derivatives (3 and 5) demonstrated enhanced oral activity.

(Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation through Biological Membranes

(Acyloxy)alkyl carbamates of the type R1R2N-CO-O-CHR3-OCO-R4 are described as novel bioreversible prodrugs for primary and secondary amines.These were prepared either by a one-step reaction involving nucleophilic attack on p-nitrophenyl α-(acyloxy)alkyl carbonates with displacement of p-nitrophenol or by reaction of α-haloalkyl carbamates with silver or mercury salts of carboxylic acids.Enzymatic hydrolysis of the ester bond in these ester carbamates leads to a cascade reaction resulting in rapid regeneration of the parent amine.Permeability measurements of such nonionic derivatives of atenolol, betaxolol, pindolol, propranolol, and timolol through fuzzy rat skin and rabbit cornea mounted on diffusion cells show that derivatization of the hydrophilic β-blockers results in several-fold increase in permeation through these biological membranes.However, prodrug modification of the lipophilic β-blockers leads to little advantage in permeability characteristics.